Study of a new drug for leukemia with certain gene changes
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug (S243249) for people with acute leukemia that has come back or not responded to treatment. It focuses on those with specific gene changes (KMT2A, NUP98, or NPM1c) and aims to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have acute leukemia (AML, ALL, or mixed lineage) that has returned or not responded to treatment.
- You must have one of three specific gene changes: KMT2A, NUP98, or NPM1c.
- You must be at least 2 weeks past your last leukemia treatment and recovered from side effects.
- You must have adequate liver, kidney, and heart function.
- You must agree to use effective birth control if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug for people with acute myeloid leukemia (AML) that has come back or hasn't responded to standard therapies, and whose leukemia has certain genetic markers. The drug may target these specific changes to help stop the cancer.
This trial tests a new drug, S241656, alone or with other treatments, for people with specific types of blood cancers like acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that have not responded to standard treatments or have come back.
This study tests a new experimental drug (NMS-03597812) for adults with AML that has not responded to or has returned after other treatments. The goal is to see if it is safe and if it can help control the leukemia.
This is a Phase 1 trial testing a new drug called BSB-2002 in patients with acute myeloid leukemia (AML) that has come back or stopped responding to previous treatments. The drug is designed specifically for patients whose cancer cells have a particular genetic change (NPM1 mutation) and may help control the cancer by activating the immune system.
This trial tests a combination of three drugs (revumenib, azacitidine, and venetoclax) for children and young adults with a hard-to-treat type of leukemia that has a specific genetic change. The goal is to see if this new mix can help when standard treatments have not worked.
This early-phase study tests a menin inhibitor drug (SNDX-5613) combined with standard induction chemotherapy (daunorubicin plus cytarabine) in newly diagnosed AML with specific gene changes (NPM1 or FLT3 status, or MLL/KMT2A or NUP98). It may help patients whose AML has these genetic features respond better to intensive treatment.
Hear when a new Relapsed or Refractory Acute Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.